Search Dental Tribune

Regedent marks a decade of hyaDENT BG in periodontitis and peri-implantitis treatment at EuroPerio11

The symposium provides practical insights into managing peri-implant mucositis and peri-implantitis using evidence-based, minimally invasive regenerative approaches. (Image: Gennady Danilkin/Adobe Stock)
Regedent

Regedent

Fri. 16. May 2025

save

VIENNA, Austria: Regedent is marking a major milestone at EuroPerio11 with a symposium highlighting ten years of clinical experience with hyaDENT BG, a cross-linked hyaluronic acid (xHyA) that has played a significant role in advancing periodontal and peri-implant therapy.

Over the past decade, the integration of hyaDENT BG with PERISOLV, a sodium hypochlorite and amino acid-based gel for subgingival decontamination, has led to the development of CLEAN&SEAL, a clinically validated protocol supporting regeneration in both surgical and non-surgical contexts.

“Clinical studies confirmed the effectiveness of non-surgical therapy with cross-linked hyaluronic acid,” said Prof. Anton Sculean, who is chairing the session. “Based on all these data, the CLEAN&SEAL concept was introduced into periodontal therapy. This represented a paradigm shift—predictable regeneration without surgery.”

Today’s symposium presents the latest clinical and preclinical findings on the role of xHyA in periodontal and peri-implant care. Attendees gain practical guidance on incorporating CLEAN&SEAL into everyday practice, especially in challenging cases involving peri-implant mucositis and peri-implantitis.

“This event marks a moment of reflection,” said Lucia Calvi, CEO of Regedent. “Ten years of clinical experience with hyaDENT BG have built a strong foundation for modern regenerative protocols. We’re excited to share this journey with the dental community.”

All participants receive a complimentary 128-page clinical handbook offering detailed case studies and hands-on guidance for applying the CLEAN&SEAL concept.

Regedent develops, manufactures and markets regenerative solutions for oral surgery, guided bone regeneration and periodontology with a focus on preserving teeth and implants. The company is known for its evidence-based cross-linked hyaluronic acid gels, biofilm-removing gels, resorbable membranes and porcine bone substitutes. The CLEAN&SEAL therapy reflects Regedent’s longstanding commitment to scientific collaboration and innovation. Regedent operates globally with offices in Switzerland, Germany and Italy.

The symposium, titled “Ten years of hyaDENT BG in periodontitis and peri-implantitis” takes place today from 12:30 to 14:00 in the Stolz 1 confenrence room at EuroPerio11. More information about the company can be found at regedent.com.

Tags:
To post a reply please login or register
advertisement